Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets

Table 2 The 19-miRNA prognostic signature and its characteristics

Signatures miRNA ID	Top 100 survival significant miRNAs selected by DDSS-1D						DDSS-1D ( with 10-fold cross validation)			DDSS-2D
Signatures miRNA ID	Log-rank P-value	Survival pheno-type^a	Cut-off	Average expression in subgroup 1	Average expression in subgroup 2	P-value in M-W test	P-value	Confidence level	CV of cutoff^b	Frequency of synergistic gene pairs (P<0.05)
hsa-miR-483-5p	9.31E-06	2	4.71	4.42	5.05	1.13E-63	3.50E-04	1	0.65%	50
hsa-miR-148a	5.07E-05	1	6.33	6.89	5.84	2.44E-78	6.66E-05	1	0.00%	57
hsa-miR-98	1.49E-04	1	4.70	5.01	4.48	2.50E-70	5.20E-03	1	0.75%	50
hsa-miR-494	1.50E-04	2	6.45	5.70	7.23	2.55E-73	8.10E-04	1	0.25%	51
hsa-miR-575	1.82E-04	2	4.91	4.67	5.30	3.01E-77	7.50E-04	1	0.06%	56
hsa-miR-136	3.02E-04	2	4.73	4.40	4.97	7.18E-39	1.40E-02	0.99995	0.48%	53
hsa-miR-143	3.33E-04	2	4.99	4.46	5.29	8.21E-28	3.40E-03	0.99993	0.61%	52
hsa-miR-214	9.47E-04	2	5.29	4.68	5.65	1.90E-43	9.10E-03	1	0.35%	59
hsa-miR-324-3p	1.36E-03	2	5.79	5.21	6.03	1.25E-20	7.20E-03	1	0.01%	51
hsa-miR-34a	2.11E-03	2	5.92	5.59	6.46	7.90E-76	3.90E-03	1	0.03%	54
hsa-miR-377	2.08E-03	2	4.19	4.12	4.57	5.80E-31	2.00E-02	0.99989	0.31%	51
hsa-miR-10b	2.76E-03	1	5.59	6.61	5.29	2.58E-58	1.20E-02	0.99996	0.30%	57
hsa-miR-192	2.99E-03	1	4.48	4.78	4.34	5.70E-75	3.30E-03	1	0.03%	52
hsa-miR-134	3.67E-03	2	5.01	4.53	5.24	9.11E-22	3.30E-03	1	0.11%	54
hsa-miR-365	3.85E-03	1	4.95	5.54	4.78	9.72E-27	1.10E-02	1	0.07%	51
hsa-miR-424	3.89E-03	1	4.90	5.58	4.69	3.70E-52	2.30E-02	0.99934	0.60%	53
hsa-miR-205	7.57E-03	1	4.48	5.75	4.20	1.28E-60	1.20E-02	0.99984	0.06%	59
hsa-miR-181d	9.38E-03	1	4.24	4.51	4.18	5.80E-31	1.24E-02	0.99966	0.05%	60

^a1:: tumor suppressor-like expression pattern 2: pro-oncogenic–like expression miRNA phenotype; defined by the relationships between predicted disease risks and expression level values of the miRNA in cancer tissue (Methods)
^bCV: coefficient of variation
*Fold change value is calculated as the ratio of the mean expression values of a miRNA of high-risk patients versus that of low-risk patients. 11 novel HG-SOC outcome predictive miRNAs are highlighted in boldface.

ISSN: 1471-2164